|

TILT-123 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (TILT-123)

Pipeline

Phase 1/2: 1

Top Sponsors

  • TILT Biotherapeutics Ltd.1

Indications

  • Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin1
  • Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin1
  • Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin1
  • Platinum-Refractory Primary Peritoneal Carcinoma1
  • Platinum-Refractory Fallopian Tube Carcinoma1

Rochester, Minnesota1 trial

Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.

Mayo Clinic

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.